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Histone H3REST (repressor element 1-silencing transcription factor) is a transcription factor that recruits histone
deacetylases to silence gene transcription. REST appears to play a paradoxical role in cancer cells: it exhibits
tumor suppressor activity or promotes tumorigenesis, depending upon the setting. The extracellular signaling
molecules that control REST gene expression in cancer cells remain poorly understood. In this study, we report
that REST expression in HeLa cells is elevated in cells exposed to epidermal growth factor or serum, whereas
the rate of cell apoptosis is low. Apoptosis induced by serum withdrawal is signiﬁcantly increased in HeLa cells
treated with an antisense phosphorothioate oligodeoxynucleotide (AS ODN) capable of down-regulating REST
expression, whereas in HeLa cells transfected with a REST expressing plasmid, REST overexpression reduces
the marked apoptosis caused, in absence of serum, by exposure to an anti-Fas receptor antibody imitating the
Fas ligand activity plus PD 98059, a blocker of extracellular signal-regulated kinase 1/2 activation. REST knock-
down also reduces mRNA levels of the antiapoptotic protein Bcl-XL whereas in HeLa cells overexpressing REST,
the reduction of Bcl-XL mRNA caused by the anti-Fas receptor antibody plus PD 98059 is signiﬁcantly decreased.
Finally, we report that acetylation of histoneH3 is increased in HeLa cells exposed to AS ODN or anti-Fas receptor
antibody, whereas it is reduced in cells transfected with the REST expressing plasmid. Our ﬁndings indicate that
REST is a novel gene regulated by EGF inHeLa cells that potentially contributes to themodulation of apoptosis via
epigenetic mechanisms.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
REST (repressor element 1-silencing transcription factor), also known
as NRSF (neuron-restricted silencing factor), is a master transcriptional
repressor that controls several aspects of neuronal function [1–3]. Fur-
thermore, REST is expressed in non-neuronal cells and in tumor cells
[3–5]. To repress gene transcription, a zinc-ﬁnger domain in REST binds
to repressor element-1 (RE-1) sites, conserved 21–23 base pair repressor
elements [5]. Approximately 1900 genes [6] and severalmicroRNAs [7] in
the human genome have been identiﬁed as direct targets of REST. RESTis of variance; AP-1, activating
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l rights reserved.facilitates chromatin remodeling and inhibits gene expression through
recruitment of multiple enzymatic co-repressor complexes, via two re-
pressor domains located at the N- and C-terminus ends of the protein
[8]. These include mSin3A [9], which may recruit histone deacetylases
(HDACs) [10], and CoREST [11], which also recruits HDACs [12]; further-
more, REST may inﬂuence histone demethylase activity [13].
Although REST represses neuronal genes, it appears to play a para-
doxical role in cancer cells: it can exert tumor suppressor activity in
some settings and oncogenic activity in others, making it a biological
enigma [5,14]. Elevated REST activity is coupled with Myc up-
regulation and may play a role in malignant transformation of cerebel-
lar neuronal cells [15]. REST, in fact, is overexpressed in medulloblasto-
ma cells that do not express target genes silenced by this transcription
factor, indicating that the REST repressor function is important in tu-
morigenesis [16]. In support of this view, the expression of REST-
VP16, an antagonistic isoform of native REST, causes the activation of
REST target genes and blocks the progression of medulloblastoma
[17]. Interestingly, expression of REST-VP16 in these cells triggers apo-
ptosis, through mechanisms that have not yet been elucidated. In con-
trast, in breast [18], prostate [19], and small cell lung cancer [20] REST
has been demonstrated to act as a tumor suppressor that promotes
cell transformation, proliferation, and migration.
In addition to REST full-length, a truncated variant named REST4,
has been described [21]. REST4 is generated by the inclusion of an al-
ternative exon into the coding region of REST that results in the
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neuroblastoma cells [22], in human small cell lung cancer [23] and in
colorectal cancer [24] and add more evidence to the potential role of
this transcription factor in tumor progression. Analysis of REST4 has
revealed that it is capable of binding to the RE-1 sequence, albeit
weakly [25], and conﬁrmed that it may form hetero-oligomers with
REST which inhibit REST binding to the RE-1 [26]. A recent publica-
tion has found that REST4 is expressed in breast cancer patients un-
dergoing early disease recurrence [27].
REST-mediated epigenetic modiﬁcations [28] may exert a strong
inﬂuence on the chromatin structure, leading to alterations in gene
expression and other nuclear functions. Among histone modiﬁca-
tions, lysine acetylation has emerged as a major post-translational
modiﬁcation [29]. Therefore, REST potentially causes chromatin com-
paction by inﬂuencing the levels of histone acetylation. Conversely,
histone acetylation unfolds chromatin and is associated with activa-
tion of transcription when REST is down-regulated [30]. Widespread
alterations in histone acetylation patterns have been previously iden-
tiﬁed during tumorigenesis [31,32] and HDAC inhibitors have been
demonstrated to possess anti-tumor activity [33]; through the promo-
tion of acetylation a diverse biological response in tumor cells occurs,
including induction of apoptosis and suppression of cell proliferation
[34].
In contrast to REST target gene regulation, the extracellular signaling
molecules andmechanisms that control REST gene expression in cancer
cells remain poorly understood. In our previous studies, we found that
this transcription factor is up-regulated by fetal calf serum and by the
trophic growth factor insulin-like growth factor-I (IGF-I) in neuroblasto-
ma cells, along with concomitant repression of neuronal differentiation
genes, as cells are maintained in an undifferentiated and proliferative
state [35,36]. Conversely, when neuroblastoma cells are forced to differ-
entiate by prolonged exposure to IGF-I [35] or retinoic acid [37], REST
expression decreases and neuronal markers increase. These studies, as
well as others [38], suggest that abnormal expression of REST in neuro-
blastoma cells blocks cell differentiation and contributes to the cancer-
ous phenotype.
In addition to IGF-I, epidermal growth factor (EGF) plays an impor-
tant role in the development and progression of solid tumors [39]. In
this study, we investigated the contribution of EGF to REST gene expres-
sion in HeLa cells, a well established model of cervical adenocarcinoma,
where the presence of human papillomavirus E6 and E7 proteins con-
tributes to alter a proper control of apoptosis [40]. Previous studies
have conﬁrmed that these cells express REST [41] and EGF receptors
that are linked to a functional signaling pathway [42]. Herein, we report
that REST is elevated in cells exposed to EGF or serum, whereas cell ap-
optosis is low. Apoptosis inducedby serumwithdrawal is signiﬁcantly in-
creased inHeLa cells treatedwith an antisense (AS) oligodeoxynucleotide
(ODN) capable of down-regulating REST expression, whereas REST over-
expression reduces apoptosis caused by exposure to an anti-Fas antibody
imitating the Fas ligand activity binding to the Fas receptor (FasR) plus PD
98059, a blocker of extracellular signal-regulated kinase 1/2 (ERK 1/2) ac-
tivation. Our ﬁndings demonstrate that apoptosis is related to activation
of caspase 3/7 and of proapoptotic caspase-3 and poly (ADP-ribose) poly-
merase 1 (PARP). Furthermore, REST knockdown also reduced mRNA
levels of the antiapoptotic protein Bcl-XL. Finally, we investigated the
acetylation of histone H3 in HeLa cells exposed to AS ODN or transfected
with a REST-expressing plasmid by Western blot analysis.
2. Materials and methods
2.1. Materials
Dulbecco's modiﬁed Eagle's medium and fetal calf serum (FCS)
were from Invitrogen (Carlsbad, CA, USA). Recombinant human EGF
was purchased from Upstate Biotechnology Inc. (UBI, Lake Placid,
NY, USA). Neutralizing anti-mouse EGF receptor antibody, anti-Fasmonoclonal antibody, used to induce apoptosis in human cell culture
by imitating the Fas ligand, anti acetyl-histone H3 and anti-histone
H3 antibodies were purchased from Millipore (Billerica, MA, USA).
Monoclonal anti-REST antibody recognizing a sequence near the N-
terminus of human REST was obtained from Abcam (Cambridge,
UK). Polyclonal anti-histone H1 antibody was purchased from ProSci
(Poway, CA, USA). Monoclonal β-actin antibody, actinomycin D
(ActD), cycloheximide (Cx), PD 98059, LY 204002, Hoechst 33258, ol-
igonucleotide primers and phosphorothioate ODNs were obtained
from Sigma-Aldrich (St. Louis, MO, USA). Nuclear and Cytoplasmatic
Extraction Reagents kit, bicinchoninic acid (BCA) protein assay, and Sup-
erSignal West Pico chemiluminescent substrate were obtained from
Pierce (Rockford, IL, USA). Protran™ was obtained from Whatman
(Kent, UK). Anti-caspase-3 antibody was purchased from Cell Signaling
(Danvers, MA, USA). Peroxidase-conjugated secondary antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Annexin
V-Fluos was obtained from Roche Applied Science (Indianapolis, IN,
USA). Polyacrylamide gel, N,N,N′,N′-tetramethylethylenediamine and so-
dium dodecyl sulfate were purchased from Sigma-Aldrich. The Caspase-
Glo 3/7 assay kit was obtained from Promega (Madison, WI, USA). Anti-
PARP monoclonal antibody was obtained from Pierce. [Methyl-3H]-thy-
midine (5 Ci/mmol) was provided by PerkinElmer Inc. (San Jose, CA,
USA). All other reagents utilizedwere of analytical grade or of the highest
purity available and purchased from Sigma-Aldrich or Roche. All plastic
disposables were from Sarstedt (Nümbrecht, Germany).
2.2. Cell culture
HeLa cells, a human cervical adenocarcinoma cell line obtained
from the American Type Culture Collection (Rockville, MD, USA),
were cultured as monolayers in Dulbecco's modiﬁed Eagle's medium
containing 1 mM sodium pyruvate, 0.1 mM nonessential amino acid,
10% (vol/vol) FCS, 100 U/ml penicillin, and 100 μg/ml streptomycin
at 37 °C in a humidiﬁed environment containing 5% CO2 and 95% air.
2.3. Total RNA preparation and real time-polymerase chain reaction (RT-
PCR) analysis
For RT-PCR experiments, HeLa cells were treated as indicated in the
various experiments, then collected, centrifuged (500 g for 5 min) and
rinsed with phosphate-buffered saline (PBS). Total cellular RNA was
extracted using Trizol® reagent (Invitrogen) and digested with RNAse-
free DNAse (Invitrogen) for 15min at 25 °C according to the man-
ufacturer's instructions. A 2-μg sample was reverse-transcribed using
theHigh-Capacity cDNAReverse Transcription Kit™ (Applied Biosystems,
Foster City, CA, USA) according to themanufacturer's instructions. RT-PCR
was employed for relative quantiﬁcation of mRNA transcripts: the
StepOne™ RT-PCR System (Applied Biosystems) was used in accordance
with themanufacturer's instructions. To amplify the 5′ cDNAREST region,
a sense primer (5′-TCGAAGACCAAACCCTTTCG-3′) and an antisense
primer (5′-GATTAGTATTGTAGCCGCAGCG-3′) amplifying a 226 bp frag-
ment (from 807 to 1026 bp) was used. To amplify Bcl-XL cDNA, a sense
primer (5′-AGAAGAAACTGAAGCAGAG-3′) and an antisense primer (5′-
TCCGACTCACCAATACCTG-3′) amplifying a 382 bp fragment was used.
As a control, a 169 bp fragment of the L19 ribosomal protein was
ampliﬁed using a sense primer (5′-CTAGTGTCCTCCGCTGTGG-3′) and
an antisense primer (5′-AAGGTGTTTTTCCGGCATC3′).
Relative expression levels of RT-PCR products were determined
using the ΔΔCt method [43]. Each sample was tested in triplicate and
the mean Ct was used in the ΔΔCt equation [36,37].
2.4. Reverse-transcription PCR to detect full-length REST and REST4
Total cellular RNAwas extracted and reverse-transcribed as previous-
ly reported. Ampliﬁcation of 200 ng of cDNAwas achievedwith 40 cycles
using Pfu polymerase provided by Fermentas (M-Medical, Milan, Italy)
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sense primer (5′-GAGCGAGTATCACTGGAGGAAACATTT-3′) and an anti-
sense primer (5′-ATAGTCACATACAGGGCAATTGAACTGC-3′) amplifying
a fragment of 415 bp from exon IV to exon VI was used [27]. Ampliﬁca-
tion of cDNA of REST4 splice variant, incorporating a 50-bp insert be-
tween exon V and exon VI [21,23], will generate a band of 465 bp. To
amplify only REST4 cDNA, we used the same sense primer employed
to amplify REST full-length and an antisense primer (5′-GCTTCTC
ACCCATCTAGATCAC-3′) generating a fragment of less than 400 bp, lo-
cated between exon IV and the end of the alternative exon included in
REST4 [27].
2.5. AS ODN experiments
TheASphosphothioateODNused in this studywas complementary to
nucleotides 390–411 of REST mRNA: (5′-TGTTGCCACTGCTGGTAAACAG-
3′, GenBank™ Accession no. NM_005612). A mismatch (MS) pho-
sphothioate ODN was designed as the negative control: (5′-GGTTACC
TCTCCTAGCCATCGG-3′) [35]. A GenBank™ search indicated that these
ODNs were not complementary to mRNA sequences in any other
human gene entered in the database to date. The ODNs were rec-
onstituted and stored as previously described by our group [36], and ad-
ministered to the cells by adding them to the Oligofectamine™ reagent
(Invitrogen) in the presence of 10% FCS, according to the manufacturer's
instructions. After 16 h, cells were cultured in SFM for 48 h.
2.6. Cell viability
Viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay performed according to
the manufacturer's protocol (Roche Applied Science, Mannheim, Ger-
many). The dye MTT is taken up and metabolized to a colored product
by viable mitochondria. Thus, the measurement of this metabolic re-
duction reaction was used as a marker of mitochondrial viability.
Brieﬂy, after the removal of medium, MTT (5 mg/10 ml of medium)
was added to each well, and the tissue culture plate was incubated
for 4 h at 37 °C. The MTT solution was removed, and 100 μl of dimeth-
yl sulfoxide was added to each well, the color intensity was assessed
with an enzyme-linked immunosorbent assay plate reader at a wave-
length of 570 nm. Each experiment was done in triplicate and repeat-
ed six times.
2.7. Cell proliferation
Cells were seeded in 24-well plates (5×103 cells/well) and grown
in FCS medium for 24 h. The cells were then starved by culturing in
serum free medium (SFM) and treated as reported in the results.
Cell proliferation was ascertained by measuring incorporation of
[3H]Thymidine added (2 μCi/ml) during the ﬁnal 5 h of incubation;
then the medium was removed and the cells were ﬁxed with 10% tri-
chloroacetic acid, washed in methanol, and lysed in 0.1 M NaOH,
followed by 0.1 M HCl and liquid scintillation counting [35]. Each ex-
periment was done in triplicate and repeated six times.
2.8. HeLa cell apoptosis
Cells were double stained with annexin V-Fluos and propidium io-
dide (PI) and apoptosis was evaluated by ﬂuorescence-activated cell
sorting (FACS) analysis. Annexin V-Fluos was used in accordance with
the manufacturer's instructions. Brieﬂy, the cells were harvested,
washed in PBS, and suspended in annexin V-Fluos labeling solution
(10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl2) with PI
(1 μg/ml). The suspension was incubated at room temperature for
10 min and analyzed using the BDFACSCanto™ II ﬂow cytometry sys-
tem (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Cells
were gated on the basis of their forward and side light scatter, withcell debris excluded from analysis. Data from 10,000 cells/sample
were analyzed using dedicated software (Becton, Dickinson and Com-
pany). Cells exhibiting positive staining with annexin V (i.e., early apo-
ptotic cells exhibiting annexin V+/PI− and late apoptotic/secondary
necrotic cells exhibiting annexin V+/PI+) were considered apoptotic.
A two-way dot plot was prepared to verify the percentage of apoptotic
cells. Annexin V−/PI− cells were used as viable cell control, and annexin
V−/PI+ cells were considered necrotic.
2.9. Hoechst 33258 cell staining
Morphological changes resulting from apoptosis were determined
by Hoechst 33258 staining. HeLa cells were cultured on glass cover-
slips coated with human collagen IV (Sigma-Aldrich) after experi-
mental treatments, the culture medium was aspirated and replaced
with 4% paraformaldehyde in PBS. Cells were ﬁxed in this solution
for 10 min at room temperature, and then washed once with PBS
and stained with 2.5 mg/ml Hoechst 33258 in PBS for 5 min at room
temperature. Following the staining procedure, cells were washed
in PBS and coverslips were mounted with glycerol: PBS (9:1, v/v) on
glass slides and observed under a ﬂuorescence microscope. Cells
exhibiting nuclear shrinkage and chromatin condensation or frag-
mentation were deﬁned as apoptotic cells [44].
2.10. Protein extraction and Western blot analysis
HeLa cells were scraped off in cold phosphate-buffered saline, cen-
trifuged and the pellet resuspended in 100 μl of CER I buffer (NE-
PER™ Extraction Reagent; Pierce, Rockford, IL, USA). After 10 min incu-
bation on ice, 5.5 ml of CER II buffer was added and the suspension was
resuspended by mixing, incubated on ice for 1 min then resuspended
again. The cytoplasmic fraction was separated by centrifugation at
16,000 g for 5 min. To obtain the nuclear extract, the cell pellet was
resuspended in 50 μl of NER buffer and incubated on ice for 40 min.
The soluble proteins in the lysate were separated by centrifugation at
16,000 g for 10 min at 4 °C. The protein content was quantiﬁed using
a BCA protein assay (Pierce). The proteins of the nuclear or of the cyto-
plasmic extract were denatured at 95 °C for 3 min, then loaded and sep-
arated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
MagicMark™ XP Western Standard (Invitrogen) served as a molecular
weight standard. Proteins were transferred to Protran™ nitrocellulose
membranes, which were blocked with 5% nonfat milk in Tris buffered
saline (10 mM Tris–HCl, pH 8), containing 150 mM NaCl plus 0.1%
Tween-20 for 1 h at room temperature (25 °C). The blots were probed
overnight at 4 °C in Tris buffered saline containing 0.1% Tween-20, 5%
nonfat milk, and the required antibody. Caspase-3 antibody detects en-
dogenous levels of procaspase-3 (approximately 35 kDa) and subunit
cleavage products of approximately 17 and 19 kDa; PARP antibody de-
tects pro-PARP (around 116 kDa) and a subunit cleavage product of ap-
proximately 85 kDa. The membranes were incubated with peroxidase
conjugated secondary antibodies at a dilution of 1:8000. Blots were ﬁ-
nally developed with SuperSignal West Pico chemiluminescent sub-
strate for 5 min. The substrate was prepared by mixing the
SuperSignal West Pico Stable Peroxidase Solution and the SuperSignal
West Pico Luminol/Enhancer Solution at a ratio of 1:1. After drainage
of the solutions, chemiluminescence was detected using a luminescent
image analyzer LAS-3000 (Fujiﬁlm, Tokyo, Japan).
2.11. Caspase 3/7 activity assay
Following experimental treatments, cells were subjected to caspase
3/7 activity analysis using a Caspase-Glo™ assay kit (Promega). Brieﬂy,
the plates containing cellswere removed from the incubator and allowed
to equilibrate at room temperature for 30 min. A volume of 100 μl of
Caspase-Glo™ reagent was added to each well. Plates were gently
mixed with a plate shaker at ≈500 rpm for 30 s and then incubated at
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mined using a plate-reading luminometer (Victor2; PerkinElmer, Wal-
tham, MA, USA).
2.12. Plasmid transfection
HeLa cells were plated in 24-well dishes and at 80%–85% conﬂu-
ence were transiently transfected with 2.0 μg/well of the plasmid
pCMV6XL4+REST (Origene, Rockville, MD, USA) containing the
cDNA coding sequence of human REST; alternatively, the mock plas-
mid pcDNA 3.1 (Invitrogen) was used as a control instead of the
REST expressing plasmid. Cell transfection was carried out using the
EXGEN 500 Transfection Reagent (Fermentas, Hanover, MD, USA).
After 16 h, cells were cultured in SFM for 48 h.
2.13. Data analysis
All data were expressed as mean±standard error of the mean (SEM)
for the number of experiments indicated. Statistical comparisons were
made by analysis of variance (ANOVA), and post-hoc Newman–Keuls;
differences of Pb0.05were considered signiﬁcant (Prismversion 4.0, Gra-
phPad Software, Inc., San Diego, CA).
3. Results
3.1. Serum and EGF up-regulate REST mRNA in HeLa cells
REST mRNA levels were measured by RT-PCR in the human cervi-
cal cancer cell line HeLa, which expresses signiﬁcant amounts of REST
[41]. In order to investigate whether REST mRNA is regulated by a
physiological source of mitogens, we tested the effect of FCS on
REST expression. Concentrations of REST mRNA were measured by
amplifying a 197 bp fragment (from 2762 to 2958 bp) located in the
3′-end region of mRNA and were signiﬁcantly higher (Pb0.01) in
HeLa cells maintained in SFM for 24 h followed by FCS (10%; v/v)
for 24 h compared to cells cultured in SFM for 48 h (Fig. 1, panel A).
Exposure of HeLa cells that were maintained in SFM for 24 h to EGF
(1–10 nM) for 24 h induced a signiﬁcant increase in steady-state
REST mRNA levels compared to cells maintained in SFM for 48 h.
REST mRNA levels began to rise at an EGF concentration of 1 nM
and exhibited a maximal increase in cells exposed to 10 nM EGF
(Fig. 1, panel A). Neutralization of the EGF receptor with a speciﬁc
monoclonal antibody (20 μg/ml; added to the cells 60 min prior to ad-
dition of the trophic agent) signiﬁcantly prevented (Pb0.01) the ac-
tion of EGF on REST mRNA expression (Fig. 1, panel A). Thus, our
ﬁndings indicate that the action of EGF on REST mRNA is mediated
by the EGF receptor.
Time-course experiments of serum-starved HeLa cells exposed to
10% FCS resulted in a rapid and stable increase in REST mRNA that
peaked after 12 h (Fig. 1, panel B). These ﬁndings indicated that
REST transcription may be inﬂuenced by trophic factors contained
in serum. Furthermore, we found that the serum response was not
inhibited by the EGF receptor blocking antibody (Fig. 1, panel B).
These latter data conﬁrmed that activation of the EGF receptor is
not strictly necessary for the serum effect, suggesting that serum in-
duction of REST mRNA may involve alternate receptor pathway(s).
The effect of EGF (10 nM) was apparent following 6 h of treatment
and reached a peak in cells exposed to this trophic factor for 12 or
24 h; in contrast to the effect elicited by serum, EGF-induced REST
mRNA levels declined and returned to basal levels in cells exposed
for 48 h (Fig. 1, panel C). To investigate whether REST mRNA up-
regulation was due to transcriptional mechanisms or whether serum
and EGF stabilized REST mRNA, we performed studies using ActD
(10 μM), an inhibitor of RNA polymerase [45] and Cx (40 μg/ml), an in-
hibitor of protein translation [46]. RNA was extracted from HeLa cells
pretreated with or without ActD or Cx for 30 min prior to the 24 hincubation with EGF in SFM or with 10% FCS. As shown in Fig. 1
(panel D), pretreatment with ActD blocked the effect of EGF or 10%
FCS on REST transcription, whereas Cx exhibited no effect. A challenge
of HeLa cells with ActD alone resulted in a signiﬁcant decrease in REST
mRNA similar to that observed in the group treated with ActD+EGF
or with ActD+10% FCS, whereas Cx alone did not affect REST mRNA
basal levels (data not shown). These results suggest that EGF or serum
alter REST gene expression primarily via transcription-dependent
mechanisms and not through stabilization of RESTmRNA. The activated
EGF receptor recruits various adaptors and signalingmolecules through
the phosphorylated cytoplasmic domain, which further leads to activa-
tion of a variety of downstream signaling pathways including the Erk1/
2 via recruitment of Grb2 [47] or Shc adaptors and the phos-
phatidylinositol 3-kinase (PI3-K)/Akt pathway [48]. Both signaling
pathways are often activated in response to mitogenic stimuli [49]
and act cooperatively to activate gene expression in response to
serum [50]. Moreover, PI3-K contributes to tumor progression through
cell cycle stimulation and protection from apoptosis [51]. We used two
selective inhibitors of these signaling cascades to determine whether
the Erk1/2 and the PI3-K pathways participate in serum- and EGF-
induced REST mRNA transcription: PD 98059, that non-competitively
blocks the activation of Erk1/2 by Raf-1 without affecting other
known serine/threonine and tyrosine kinases and LY 294002, a blocker
of the PI3-K pathway [52]. In HeLa cells exposed for 24 h to 10 nM EGF
in SFM or to 10% FCS, PD 98059 or LY 294002 (50 μM) signiﬁcantly re-
duced steady-state levels of mRNA coding for REST (Fig. 1, panel D),
whereas, when administered alone in SFM cultured cells, neither
agent inﬂuenced the basal level of REST mRNA (data not shown). Both
of the inhibitors prevented serum- and EGF-induced REST expression;
thus, our ﬁndings demonstrate that both pathways contribute to the ef-
fect of serum and EGF on expression of this transcription factor in HeLa
cells.3.2. EGF and AS-ODN targeting REST mRNA regulate REST nuclear
content
The levels of the corresponding REST protein in nuclear extracts of
HeLa cells exposed to EGF or SFM were evaluated by Western blot
(Fig. 2, panels A and B) and followed a pattern similar to mRNA ex-
pression. REST levels were increased in a concentration-dependent
manner in cells exposed to EGF (1–10 nM) for 24 h in SFM (Fig. 2,
panel A) whereas they were signiﬁcantly reduced in cells incubated
for 24 or 48 h in SFM (Fig. 2, panel B).
In order to investigate the impact of REST on apoptosis in HeLa
cells, we developed a strategy based on the administration of an AS
ODN that targeted REST mRNA and was capable of down-regulating
the expression of this transcription factor. As ascertained by Western
blot analysis, exposure to AS ODN (1 μM) in SFM resulted in a signif-
icant reduction of nuclear REST levels, whereas cells cultured in the
presence of an MS ODN (1 μM) exhibited REST levels similar to con-
trol cells maintained in SFM (Fig. 2, panel C); thus, our ﬁndings indi-
cate a sequence-speciﬁc down-regulation of this protein by AS ODN.
AS ODN was equally effective in HeLa cells maintained in FCS (data
not shown). A lower concentration of AS ODN (0.5 μM)was less effec-
tive, whereas higher concentrations of ODNs (>10 μM) reduced cell
viability regardless of their sequence, and thus were not used (data
not shown).
HeLa cell viability was not inﬂuenced by 1 μM AS ODN in cells
maintained in 10% FCS. Conversely, in 48-h serum withdrawal cells, a
slight reduction of cell viability was observed and REST-depleted HeLa
cells in SFM revealed a distinctly decreased cell viability in comparison
to MS ODN treated cells or untreated cells in SFM (Fig. 2, panel D). In a
separate set of experiments, we investigated the proliferation of HeLa
cells exposed to AS ODN or MS ODN (1 μM). Exposure to each ODN
(1 μM) for 48 h in SFM did not exhibit a signiﬁcant effect on cell
Fig. 1. EGF and 10% fetal calf serum (FCS) up-regulate steady-state levels of REST mRNA in HeLa cells. Relative fold changes of the REST gene following various treatments were
calculated using the ΔΔCt method as described in the Materials and methods section. (A) Exposure to 10% FCS or EGF (1–10 nM) for 24 h increases REST mRNA levels compared
to cells maintained in serum free medium (SFM) for 48 h. The action of EGF on REST mRNA was reduced by neutralization of the EGF receptor with a speciﬁc monoclonal antibody
(20 μg/ml, Ab; added 60 min before 10 nM EGF). (B) Time-dependent effect increase of REST mRNA in cells maintained in SFM for 24 h and exposed to 10% FCS for 6, 12, 24 and
48 h. The action of 10% FCS on REST mRNA was not blocked by the monoclonal antibody capable of neutralizing EGF receptor. (C) Time-dependent change of REST mRNA levels
in cells exposed to EGF (10 nM) for 6, 12, 24 and 48 h. (D) Effect of actinomycin D (Act D), cycloheximide (Cx), PD 98059, and LY 294002 on EGF- or FCS-induced REST mRNA
up-regulation. HeLa cells were maintained for 48 g in SFM or for 24 h in SFM and then incubated with 10 nM EGF or 10% FCS for 24 h and with Act D (10 μM) or Cx (40 μg/ml)
(these were added 30 min prior to the 24 h incubation with EGF in SFM or with 10% FCS), or in the presence of PD 98059 or LY 294002 (50 μM each; added 60 min before EGF).
Values are mean±SEM of at least six independent experiments conducted in triplicate using different cell cultures. *Pb0.05; **Pb0.01 vs. SFM 48 h; ##Pb0.01 vs. SFM+EGF
10 nM or vs. SFM24h+FCS24h (Newman–Keuls test after ANOVA).
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ed as change of [3H]thymidine incorporation; data not shown).
3.3. Full-length REST is expressed in HeLa cells
To investigate the occurrence of REST4mRNA inHeLa cells, we ampli-
ﬁed a cDNA sequence of ≈415 bp, using a set of primers ﬂanking the
REST4 alternative exon. This analysis detected only one band
corresponding to REST full-lengthmRNAwhereas cDNA fragment, incor-
porating an additional 50-bp insert as in the REST4 splice variant, was no
longer observed. Selective ampliﬁcation of REST4 cDNA using a reverse
primer placed in the REST4 alternative exon, ruled out the occurrence
of this splice variant in HeLa cells (Fig. 3, panel A). Thus, in agreement
with other studies [53,54], only full length REST mRNA is expressed in
HeLa cells.
Western blot analysis conﬁrmed that in HeLa cells only a single form
of REST protein with an apparent molecular weight of ≈200 kDa is
expressed; no truncated form corresponding to REST4 was detected
(this truncated protein should have an apparent molecular weight of
≈51 kDa, [21]) (Fig. 3, panel B).
3.4. Effect of AS-ODN targeting REST mRNA on HeLa apoptosis
As reported in Fig. 4, the reduction of cell viability observed in
serum withdrawal cells treated with AS ODN was mainly due to the
apoptotic cell fraction. We evaluated the ability of HeLa cells cultured
for 48 h in SFM to bind annexin V and exclude PI, and, as expected, thecells exhibited moderate spontaneous apoptosis as determined by
ﬂow cytometry (Fig. 4, panels A and B). Furthermore, exposure to AS
ODN (1 μM) in SFM for 48 h signiﬁcantly increased serum starvation
apoptosis. This effect was not observed in MS ODN (0.5 or 1 μM) treat-
ed cells or in cells treated with a lower concentration of AS ODN
(0.5 μM) (Fig. 4, panels A and B). Finally, we found that EGF (10 nM),
added during the last 24 h to cells maintained in SFM or exposed to
MS ODN, signiﬁcantly reduced serum starvation apoptosis, whereas
partially reversed apoptosis induced by 1 μMAS ODN (Fig. 4, panel A).
AS ODN (1 μM; 48 h) added to cells routinely maintained in 10% FCS
did not induce any signiﬁcant apoptosis (data not shown). Thus, con-
ﬁrming that trophic factors contained in serummay counteract apopto-
sis induced by REST down-regulation.
Apoptosis caused by AS ODN in SFM cells was conﬁrmed by Hoechst
33342 staining,which allowed to visualize the characteristicmorpholog-
ic features elicited by cell apoptosis. Staining with this compound
exhibited a more diffuse fragmentation and condensation of chromatin
in HeLa cells treated with AS ODN (1 μM) in SFM compared to cells cul-
tured in SFM alone. Control cells, maintained in FCS, exhibited normal
nuclear morphology, characterized by a diffuse chromatin structure
and, therefore, light staining (Fig. 4, panel C).
3.5. Effect of AS ODN targeting REST mRNA on caspase activity
To determine whether caspases are activated during the apoptosis
induced by the REST down-regulation produced by AS ODN, we ex-
amined caspase-3/7 activity in HeLa cells treated as described
Fig. 2. Effect of EGF, 10% fetal calf serum (FCS), antisense (AS) ormismatch (MS) oligodeoxynucleotide (ODN) onnuclear levels of REST inHeLa cells or on cell viability. Cellswere cultured
in serum free medium (SFM) and treated with EGF or an ODN. (A) Exposure to EGF (1–10 nM; added for 24 h in cells maintained for 24 h in SFM) increases REST protein levels in com-
parison to cells maintained in SFM for 48 h. (B) Exposure to SFM for 24 and 48 h down-regulates REST nuclear content in comparison to control cells maintained in 10% FCS (Ctrl). (C) AS
ODN inhibition of REST expression in HeLa cells. An AS ODN complementary to RESTmRNA down-regulates REST nuclear protein levels in HeLa cells maintained in SFM. Cells were trans-
fectedwith AS orMSODN (1 μM) as described in theMaterials andmethods section and for 48 h incubated in SFM. RepresentativeWestern blot experiments and densitometric analyses
of the bands (mean±SEM; n=6) are shown. Histone H1was evaluated in the same samples and used for loading control. The approximatemolecularmass of REST (only a single band of
≈200 kDawas observed) and of Histone H1were determined by comparisonwithmolecularmass standards. (D) Effects of antisense AS ODN targeting RESTmRNA onHeLa cell viability
evaluated by theMTT assay. HeLa cellswere transfectedwith ASormismatch (MS)ODNs (1 μM)as described in theMaterials andmethods section and for 48 hwere incubated in 10% FCS
or in SFM. Values are mean±SEM of six independent experiments carried out using different cell cultures. *Pb0.05; **Pb0.01; ***Pb0.001 vs. Ctrl. #Pb0.05; ##Pb0.01; ###Pb0.001 vs.
SFM 48 h (Newman–Keuls test after ANOVA).
Fig. 3. Expression of full-length REST in HeLa cells. (A) A representative experiment of
reverse transcription PCR in HeLa cells carried out with a REST primer set ﬂanking the
REST alternative intron/exon junction or with a REST4 primer set that targets the
REST4 alternative exon. (B) A representative Western blot analysis of REST protein
expressed in HeLa cells. Only one single band corresponding to full-length REST
(≈200 kDa) was detected. The migration of the molecular weight marker is shown
in the left lane. Each experiment, carried out as described in the Materials and methods
section, was repeated six times with similar results using different cell cultures.
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signiﬁcant increase in caspase-3/7 activity; this was further elevated
by the addition of 1 μM AS ODN, whereas a lower concentration of
AS ODN (0.5 μM) or exposure to MS ODN (0.5 and 1 μM) did not pro-
duce a signiﬁcant increase of caspase-3/7 over SFM maintained cells
(Fig. 5, panel A). Upon addition of EGF (10 nM) to serum-free cells or
to cells exposed to MS ODN, caspase-3/7 activity was reduced, whereas
EGF only partially reduced caspase-3/7 activity in cells treated with
1 μM AS OD (Fig. 5, panel A).3.6. Effect of AS ODN targeting REST mRNA on the cleavage of caspase-3
and PARP
To further characterize HeLa cell apoptosis induced by AS ODN,
cleavage of caspase-3 and PARP were examined byWestern blot analy-
sis. Exposure of HeLa cells to SFM resulted in a moderate formation of
≈19 and 17 kDa fragments of caspase-3 from ≈35 kDa procaspase-3
and of ≈85 kDa protein fragment from the intact PARP (≈116 kDa)
(Fig. 5, panels B and C). The expression levels of cleaved caspase-3 and
PARP fragment were more markedly increased in cells treated with
1 μM AS ODN in SFM. Interestingly, EGF (10 nM; 24 h) added to HeLa
cells cultured in SFM decreased caspase-3 and PARP fragmentation,
Fig. 4. Effects of antisense (AS) oligodeoxynucleotide (ODN) targeting REST mRNA on HeLa cell apoptosis. HeLa cells were transfected with AS or mismatch (MS) ODNs (0.5 and
1 μM) as described in the Materials and methods section and for 48 h were incubated in SFM. EGF (10 nM; 24 h) was added to cells maintained for 24 h in SFM or where indicated
it was added during the last 24 h to ODN treated cells. Control cells were cultured in FCS (Ctrl). Apoptosis was determined by ﬂow cytometry to evaluate the ability of the cell to
bind annexin V, as described in the Materials and methods section. (A) Results are presented as the percentage of apoptotic cells. Mean±SEM from six experiments conducted in
triplicate using different cell cultures. **Pb0.01, ***Pb0.001 vs. Ctrl. #Pb0.05, ##Pb0.01, vs. SFM 48 h (Newman–Keuls test after ANOVA). (B) A representative experiment
exhibiting the percentage of apoptotic HeLa cells (annexin V+/PI− and annexin V+/PI+ cells). (C) A representative experiment exhibiting nuclear morphology observed by staining
with the nuclear ﬂuorochrome Hoechst 33258, as described in the Materials and methods section. Cells exhibiting nuclear shrinkage and chromatin condensation or fragmentation
were more frequently observed in AS oligonucleotide-treated cells compared to cells treated with MS oligonucleotide or maintained in SFM. Chromatin condensation or fragmen-
tation was rarely observed in control cells cultured in FCS (CTRL). Apoptotic cells were evaluated on at least four independent slides. Each experiment was repeated six times with
similar results using different cell cultures. Arrows indicate the nuclei of apoptotic cells. Scale bar=10 μm.
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with AS ODN (Fig. 5, panels B and C).
3.7. Effect of REST overexpression on HeLa apoptosis induced by the acti-
vation of the FasR
The FasR is an important mediator of apoptosis. However, it has
been reported that several FasR-expressing cell lines are less prone to
apoptotic signaling as a consequence of FasR-induced Erk1/2 activation,
which in turn interferes with caspase activation [55]. Previously, it has
been reported that stimulation of FasRwith an activating antibody asso-
ciated with PD 98059, a blocker of ERK 1/2 activation, induces a more
pronounced apoptosis of HeLa cells than the FaR antibody alone [55].
Therefore, we adopted this strategy to investigate the effect of REST
upon HeLa apoptosis induced by PD 98059 administered 30 min prior
to the anti-FasR antibody. These experiments were conducted in HeLa
cells transfected with the REST expressing plasmid pCMV6XL4 or with
a pcDNA3.1 empty vector.Western blot analysis conﬁrmed that a signif-
icant increase in REST nuclear levels occurs, 72 h later, in cells trans-
fected with the pCMV6XL4 plasmid and incubated for the last 48 h in
SFM (Fig. 6, panel A). PD 98059+FasR antibody, after 24 h, induces sig-
niﬁcant apoptosis in HeLa cells incubated in SFM or in cells transfectedFig. 5. Effects of antisense (AS) oligodeoxynucleotide (ODN) targeting RESTmRNA on ac-
tivation of caspase-3/7, caspase 3 and PARP fragmentation. HeLa cells were transfected
with AS or mismatch (MS) ODNs (0.5 and 1 μM) and for 48 h were incubated in SFM.
EGF (10 nM; 24 h) was added to cells maintained for 24 h in SFM or where indicated it
was added during the last 24 h to ODN treated cells. Control cells were cultured in FCS
(Ctrl). (A) Caspase-3/7 activity was measured as described in the Materials and methods
section. Data aremean±SEM from six experiments conducted in triplicate using different
cell cultures. ⁎Pb0.05, ⁎⁎Pb0.01, ⁎⁎⁎Pb0.001 vs. Ctrl. #Pb0.05; ##Pb0.01, vs. SFM 48 h.
§§Pb0.01 vs. SFM 24 h+EGF (Newman–Keuls test after ANOVA). (B) Caspase-3 and (C)
PARP cleavage were evaluated in cytosolic fractions byWestern blot analysis as described
in theMaterials andmethods section. β-actin (≈42 kDa)was evaluated in the same sam-
ples and used for loading control. The approximate molecular mass of investigated pro-
teins was determined by comparison with molecular mass standards. Representative
experiments, repeated at least six times with similar results and using different cell cul-
tures are shown.with an empty pcDNA3.1 plasmid and maintained in SFM for 48 h. This
ﬁndingwas based upon evaluation of the ability of cells to bind annexin
V (Fig. 6, panel B), to increase caspase-3/7 activity (Fig. 6, panel C),
caspase-3 (Fig. 6, panel D) and PARP cleavage (Fig. 6, panel E). Interest-
ingly, apoptosis was markedly reduced in HeLa cells overexpressing
REST in the nuclear compartment (Fig. 6, panels B–E). Themoderate ap-
optosis induced by serum withdrawal (see Fig. 4) did not allow
ascertaining any signiﬁcant effect of REST overexpression in this model
of cell apoptosis (data not shown).
3.8. Effect of AS ODN and REST overexpression on mRNA levels of the
anti-apoptotic marker Bcl-XL
Pro-apoptotic and anti-apoptotic members of the Bcl-2 family
contribute to inﬂuence cell death [56]. To further explore the mecha-
nisms that may contribute to apoptosis regulated by REST, we evalu-
ated mRNA levels of the anti-apoptotic Bcl-XL. Exposure of HeLa cells
to the AS ODN or to the FasR antibody plus PD 98059 in SFM, pro-
duced a signiﬁcant reduction of Bcl-XL mRNA levels in comparison
to cells maintained in SFM or treated with the MS ODN. Only a slight
decrease of Bcl-XL mRNA was observed in cells maintained in SFM vs.
controls left in 10% FCS (Fig. 7). Interestingly, reduction of Bcl-XL
mRNA induced by FasR antibody plus PD 98059 was not observed in
HeLa cells overexpressing REST in the nuclear compartment whereas
it was noticed in cells transfected with a pcDNA3.1 empty vector
(Fig. 7).
3.9. Acetylation of histone H3 is regulated by AS ODN and REST
overexpression
Previous studies have demonstrated that nuclear REST recruits
histone deacetylase to generate a region of hypoacetylated core his-
tone around the RE1 region of the target genes and thus repress tran-
scription [30]. Because histone H3 is among the targets of REST-
mediated deacetylation [28], we examined the acetylation status of
histone H3 in HeLa cells treated with AS ODN or overexpressing
REST. As shown in Fig. 8, a signiﬁcant increase of histone H3 acetyla-
tion was detected in cells exposed to AS ODN (1 μM). MS ODN-treated
cells (1 μM) did not present any further increase of the acetylation
status of histone H3 over cells maintained in SFM alone. Furthermore,
in cells exposed to the FasR antibody plus PD 98059 a signiﬁcant acet-
ylation of histone H3 was noted and it was signiﬁcantly reduced in
HeLa cells overexpressing REST. Examination of total histone H3 did
not indicate a signiﬁcant change of the nuclear content of this protein
(Fig. 8). Thus, we propose that REST down-regulation or over-
expression does not inﬂuence histone H3 protein expression, but only
the acetylated form.
4. Discussion
In this study, we found that nuclear levels of the transcription fac-
tor REST are reduced in a time-dependent manner in HeLa cells cul-
tured in SFM, whereas the levels are up-regulated in cells exposed
to 10% FCS or to EGF. We investigated REST expression by evaluating
the abundance of mRNA transcripts as well as nuclear protein levels
by Western blot analysis. We utilized a real-time PCR technique that
allowed us to quantify REST transcripts that correspond to the entire
sequence of REST mRNA, which appears to be the unique form tran-
scribed in HeLa cells; in contrast, the splice variant REST4 that has
been previously described in other cancer cell lines [22,23,27] was
not detected.
According to our ﬁndings, REST appears to be a novel gene regu-
lated by EGF through EGF receptor (EGFR) that requires the signaling
pathways that activate Erk1/2 and phosphatidylinositol 3-kinase
(PI3K)/Akt. Both signaling pathways contribute to EGF-mediated
cell proliferation and survival [48] and, as previously reported, they
Fig. 6. REST overexpression counteracts apoptosis induced by a Fas receptor antibody (Fas) that is capable of activating this receptor plus PD 98059. (A) HeLa cells were transfected
with the REST expressing plasmid pCMV6XL4 (REST) or with a pcDNA3.1 empty vector (empty) as described in the Materials and methods section and maintained for the last 48 h
in SFM. After 72 h from transfection, cells were collected and REST nuclear levels were evaluated by Western blot analysis. Histone H1 was evaluated in the samples and used as a
loading control. The approximate molecular mass of REST (only a single band of ≈200 kDa was observed) was determined by comparison with molecular mass standards. A rep-
resentative experiment, repeated six times with similar results using different cell cultures, is shown. ⁎⁎⁎Pb0.001 vs. Ctrl cells (Newman–Keuls test after ANOVA). HeLa cell apo-
ptosis was induced by 30 μM PD 98059 plus 100 ng of a Fas receptor antibody (PD+Fas), added for 24 h to cells in SFM or to cells transfected 48 h in advance with the REST
expressing plasmid (REST) or with an empty plasmid (empty) and determined: (B) by ﬂow cytometry, evaluating cell's ability to bind annexin V and exclude propidium iodide;
and (C) by measuring caspase-3/7 activity. Mean±SEM from six experiments conducted in triplicate using different cell cultures. ⁎Pb0.05, ⁎⁎⁎Pb0.001 vs. Ctrl. ##Pb0.01, vs.
SFM+PD+Fas+empty (Newman–Keuls test after ANOVA). Furthermore, Hela cell apoptosis was ascertained by evaluating: (D) caspase-3 and (E) PARP fragmentation by West-
ern blot analysis. Control cells were maintained in FCS. These procedures are described in the Materials and methods section. A representative experiment, repeated at least six
times using different cell cultures with similar results is shown.
Fig. 7. Effect of antisense (AS) oligodeoxynucleotide (ODN) targeting REST mRNA or
REST overexpression on mRNA levels of Bcl-XL. Apoptosis was induced, as previously
reported, by SFM and by a Fas receptor antibody (Fas) that is capable of activating
this receptor plus PD 98059 (PD+Fas). HeLa cells were transfected with the REST ex-
pressing plasmid pCMV6XL4 (REST) or with a pcDNA3.1 empty vector (empty) as de-
scribed in the Materials and methods section and maintained for the last 48 h in SFM.
Relative fold changes of the Bcl-XL mRNA levels, following various treatments, were
calculated using the ΔΔCt method as described in the Materials and methods section.
Mean±SEM from six experiments using different cell cultures are shown. ⁎⁎Pb0.01
vs. Ctrl. ##Pb0.01, vs. SFM. §§Pb0.01 vs. SFM+PD+Fas or SFM+PD+Fas+empty
(Newman–Keuls test after ANOVA).
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or overexpression of EGF receptors is common in various cancers
[58,59] where it contributes to the anti-apoptotic activity in a proper
cellular environment [60].
Serum contains a mixture of growth factors, cytokines, and other
mitogens important for cultured cells and tissues in vivo [61]. The cel-
lular proliferative response to serum has been extensively studied
previously and is characterized by rapid activation of the mitogen-
activated protein kinase pathways and the induction of immediate
early genes, many of which encode members of the activating
protein-1 (AP-1) transcription factor family (c-fos and c-jun) [62].
We found that serum stimulation of HeLa cells causes a rapid increase
in REST gene transcription, independent of EGFR. Furthermore, we
characterized this response with respect to the PI3-K and Erk 1/2
pathways that are sensitive to EGF signaling in HeLa cells [63].
Our ﬁnding that REST is reduced in serum-withdrawal cells con-
ﬁrms that this transcription factor may be regulated by growth fac-
tors that are abundant in the serum added to the cell culture
medium. In concordance with this ﬁnding, we previously reported
that REST is stimulated by serum or IGF-I in neuroblastoma cells [35].
Apoptosis induced by serum starvation is generally considered to
be caspase dependent. These death speciﬁc cysteine proteases act in
concert with destruction of initiated cells in a complex network
[64]. Caspase-3 and caspase-6 were identiﬁed as executioner caspases
after growth factor withdrawal and initiate activation of caspase-12
during serum starvation induced apoptosis [65]. In concordance with
this hypothesis, we demonstrated that serum withdrawal involves
caspases and that this event is potentiated by REST knockdown.
It is commonly accepted that EGF induces the proliferation of sev-
eral cancer cell lines and protects them from apoptosis if cultured in
SFM [66]. In this study, we demonstrated that REST protects HeLa
Fig. 8. Antisense (AS) oligodeoxynucleotide and REST overexpression modify histone H3 acetylation. HeLa cells were transfected with AS or mismatch (MS) ODNs (1 μM) and for
48 h were incubated in SFM whereas control cells were cultured in FCS (Ctrl). In another set of experiments, cells were transfected with the REST expressing plasmid pCMV6XL4
(REST), maintained in SFM for 48 h and exposed during the last 24 h to the Fas receptor antibody plus PD 98059 (PD+Fas). Alternatively, PD and Fas were added to SFM treated
cells. Cell nuclear extracts were prepared and subjected to Western blot analysis for acetylated (ac) histone H3, histone H3 and histone H1 as loading controls. A representative
experiment, repeated six times with similar results and densitometric analysis of the bands (mean±SEM; n=6) are shown. **Pb0.01, **Pb0.01 vs. Ctrl. §§Pb0.01 vs. SFM.
##Pb0.01 vs. SFM+PD+Fas. °Pb0.05 vs. SFM (Newman–Keuls test after ANOVA).
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tion and survival. This assumption was conﬁrmed by experiments
that we conducted by down-regulating REST expression targeting of
REST mRNA with an AS ODN. Under these conditions, AS ODN treated
cells exhibited more marked apoptosis compared to cells cultured in
SFM; furthermore, EGF was less effective in protecting AS ODN-
treated HeLa cells from apoptosis compared to MS ODN-treated cells.
Interestingly, in HeLa cells overexpressing REST the apoptosis in-
duced by the Fas receptor antibody in addition to PD 98059, that
non-competitively blocks the activation of Erk1/2 by Raf-1 [55], was
signiﬁcantly reduced.
In HeLa cells exposed to the AS ODN or to the FasR antibody, de-
creased mRNA levels of the prosurvival protein Bcl-xL were observed.
Romorini et al. [66] have demonstrated that in HC11mammary epithe-
lial cells the protective effect of EGF correlates mainly with the up-
regulation of Bcl-XL through PI3-K/AKT and c-Jun N-terminal kinases.
Furthermore, this growth factor, may also lead to the phosporylation
and down-regulation of the proapoptotic protein Bad. In our study, we
have demonstrated that EGF up-regulates REST transcription through
PI3-K/AKT and ERK 1/2; therefore, in absence of EGF, Bcl-XL and REST
are down-regulated whereas proaptotic proteins may be up-regulated.
In REST overexpressing HeLa cells, Bcl-XL mRNA levels were similar to
those evaluated in control cells maintained in 10% FCS; this effect
could be related to the complex REST-mediated histone modiﬁcations
in the genoma rather than to a direct action on Bcl-XL transcription. In
fact, REST binding to the RE-1 sites induces context-dependent chroma-
tin remolding, including nucleosome repositioning, systemic decline of
local histone acetylations and other key histone modiﬁcations, not re-
stricted to gene promoter regions [67]. Thus, REST recruits with other
co-repressors like CoREST and mSin3A, HDACs of class I [68,69] that in-
clude HDACs 1, 2, 3 and 8 predominantly localized in the nucleus [70]
and promotes a complex chromatin remolding across extended chro-
mosomal intervals [71] that may cause epigenetic modiﬁcations con-
tributing to maintain Bcl-XL transcription.
Conversely, HDAC inhibitors contribute to acetylate histone and
non histone proteins, including those involved in transcription factor
complexes that regulate gene expression [72]. Interestingly, Peart elal. [73], using DNA microarrays, have found that Bcl-XL, as well as
other genes contributing to apoptosis, are down-regulated in cycling leu-
kemic cells treatedwith the HDAC inhibitor suberoylanilide hydroxamic.
In this study, we observed a signiﬁcant increase in the acetylation
of histone H3 in HeLa cells exposed to AS ODN, in serum withdrawal
cells concomitant with down-regulation of REST. In contrast, this ef-
fect was not observed in cells transfected with REST expressing
plasmid.
The levels of histone acetylation in the cell depend on the oppos-
ing activities of two enzymatic classes: histone acetyltransferases and
histone deacetylases [74]. When REST is reduced or is absent, it can-
not form any effective complex with other co-repressors to inhibit
histone acetylation; in these conditions, the activity of histone
acetylases is promoted: chromatin is unfolded and favors the activa-
tion of transcription. In contrast, in the native form REST recruits
HDACs, which counteract gene transcription.
Importantly, HDACs of class I appear to be a critical controller of
apoptosis [75,76]. Many transcription factors regulated by HDACs of
class I are important for apoptosis, including nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) and E2F [77]. More-
over, the inactivation of HDAC-3, belonging to HDACs of class I, favors
apoptosis [78]. Therefore, speciﬁc modiﬁcations of chromatin are like-
ly to play an important role in apoptosis control. Indeed, the induc-
tion of histone acetylation using HDAC inhibitors is often sufﬁcient
to induce apoptosis [33,34]. Moreover, the activation of proapoptotic
genes and the inactivation of antiapoptotic genes that occur during
apoptosis are linked to speciﬁc changes in histone-induced promoter
modiﬁcations [32]. This hypothesis is further strengthened by studies
on HDAC inhibitors that have demonstrated that their antitumor ac-
tivity related to the grade of histone acetylation causes apoptosis as
well [34].
In the present study, the antiapoptotic effect elicited by REST was
observed in HeLa cells expressing only the full length of REST and not
any truncated form that has been detected in other cancer cell lines
[22,23]. Our data on the antiapoptotic role played by REST in cancer
HeLa cells conﬁrm the data of Lawinger et al. [16] and Fuller et al.
[17] in medulloblastoma cells.
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lost in breast cancer and that patients with REST-less breast cancer
undergo signiﬁcantly earlier disease recurrence. The evolution of
adaptive mechanisms provides cancer cells with the ability to evade
apoptotic execution and bestows a survival advantage [79]. It is pos-
sible that truncated forms of REST, or even its disappearance in late
stage tumors, may contribute to the dysregulation of numerous target
genes that favor cancer cell resistance instead of promoting apoptosis.
However, this latter hypothesis needs to be adequately supported by
in vivo studies that we are developing in our laboratory.
5. Conclusion
In conclusion, we proved that REST is a novel gene regulated by
EGF in HeLa cells that potentially contributes to the modulation of ap-
optosis via epigenetic mechanisms. However, its role played in cancer
cells remains to be further elucidated and further studies regarding
the epigenetic role in apoptosis of tumor cells are warranted.
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